Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FDDJW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LC-K149C-3
|
|||||
| Synonyms |
LC-K149C-3
Click to Show/Hide
|
|||||
| Organization |
National Institute of Health Sciences
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.8-2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site specific conjugation at HC-S400C.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.07 nM | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
SK-BR-3 cells (a HER2-positive cell line) were seeded at 2000 cells/well in a 96-well plate and incubated overnight at 37°C in a humidified atmosphere containing 5% CO2. The cells were treated with serially diluted homogeneous ADCs and incubated for 4 days at 37°C in a humidified atmosphere containing 5% CO2. The cytotoxicity was evaluated using the Cell Counting Kit SF (Nacalai Tesque). Each dose-response curve was fitted by 4-parameter logistic model with same upper/lower asymptotes using GraphPad prism 7 software, and calculated IC50 of homogeneous ADCs
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
References
